Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aztreonam

D H Johnson1, B A Cunha

  • 1Infectious Disease Division, Winthrop-University Hospital, Mineola, New York, USA.

The Medical Clinics of North America
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Aztreonam is a valuable antibiotic for aerobic gram-negative infections, offering an alternative to aminoglycosides due to its safety profile. However, it requires combination therapy for mixed infections and should be used judiciously to prevent resistance, particularly in Pseudomonas aeruginosa strains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Viral influenza-like illnesses: dynamic interrelationships during the 2015-2016 influenza season in hospitalized patients.

The Journal of hospital infection·2017
Same author

Editor's Mail.

Postgraduate medicine·2016
Same author

Are atypical lymphocytes present with viral influenza-like illnesses (ILIs) in hospitalized adults?

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2016
Same author

Problems+Solutions.

Postgraduate medicine·2016
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Aztreonam is a monocyclic beta-lactam antibiotic with selective activity against aerobic gram-negative bacilli.
  • It presents a favorable safety profile, lacking ototoxicity and nephrotoxicity, making it a viable alternative to aminoglycosides.
  • Its utility extends to treating infections caused by aminoglycoside-resistant gram-negative organisms, frequently implicated in nosocomial infections.

Purpose of the Study:

  • To review the clinical applications and limitations of aztreonam.
  • To highlight its role as an alternative to potentially more toxic antibiotics.
  • To emphasize the importance of appropriate usage to mitigate antimicrobial resistance.

Main Methods:

  • Review of existing clinical data and pharmacological studies on aztreonam.

Related Experiment Videos

  • Analysis of aztreonam's spectrum of activity, safety profile, and resistance patterns.
  • Evaluation of its use in monotherapy versus combination therapy.

    • Main Results:

    • Aztreonam demonstrates excellent activity against aerobic gram-negative bacteria, including many resistant strains.
    • It is a safe alternative to aminoglycosides, particularly in patients with renal or auditory concerns.
    • Combination therapy is essential for polymicrobial infections or empiric treatment to cover gram-positive and anaerobic pathogens.

    Conclusions:

    • Aztreonam is a crucial therapeutic option for aerobic gram-negative bacterial infections.
    • Judicious use is paramount to prevent the emergence of resistance, especially in Pseudomonas aeruginosa.
    • Its use should be limited to specific indications, avoiding routine addition to beta-lactam regimens for broader coverage outside of P. aeruginosa infections.